MATFIX CLASS I RECALL OF LIFEDEFENSE PLUS DEFIBRILLATOR/MONITOR/PACER
This article was originally published in The Gray Sheet
MATFIX CLASS I RECALL OF LIFEDEFENSE PLUS DEFIBRILLATOR/MONITOR/PACER is more than 50% complete, the firm says. Of the 656 units affected by the July 6 recall, 366 units distributed in the United States already have been returned. Matrx expects that approximately 150 additional units sold in the U.S. will be returned to the firm within a month. The remaining devices, which were distributed to Europe, South America, and the Pacific Rim, are on target to be returned by a February deadline, according to the company.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.